Trial Profile
Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms FiTNEss; FiTNEss (UK-MRA Myeloma XIV)
- 04 Mar 2024 Planned End Date changed from 1 Dec 2024 to 31 Aug 2027.
- 12 Dec 2023 Results(n=559) assessing patient-reported outcomes to understand HRQoL according to frailty group and the contribution of different elements of the International Myeloma Working Group presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition